Concepedia
Statistics
Publications
13
Citations
665
H-Index
Active since
1997
Affiliations
Kyowa Kirin (Japan)(Current)
Novartis (Japan)
Novartis (Switzerland)
Kindai University
Osaka Prefectural Medical Center
Hiromi Tanii is an author at Kyowa Kirin (Japan) specializing in medicine, pharmacology, and pharmacotherapy.
Top concepts
MedicinePharmacologyPharmacotherapyOncologyCancer ResearchRadiation OncologyClinical PharmacologyPathologyBiochemistryGlycobiology
Publications per year
1997–2011
Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein.
Eiichi Fuse, Hiromi Tanii, Noriaki Kurata et al. · PubMed · 1998 · 203 citations
Molecular Pharmacology, Alpha1-acid Glycoprotein, Unusual Pharmacokinetics +14
Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models
Edward A. Sausville, Richard D. Lush, Donna Headlee et al. · Cancer Chemotherapy and Pharmacology · 1998 · 89 citations
Molecular Pharmacology, Pharmacological Study, Preclinical Models +6
Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans.
Eiichi Fuse, Hiromi Tanii, K Takai et al. · PubMed · 1999 · 73 citations
Alpha1-acid Glycoprotein, Altered Pharmacokinetics, Biochemistry +14
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
Akira Fukutomi, Kiyohiko Hatake, Kaoru Matsui et al. · Investigational New Drugs · 2011 · 46 citations
Pancoast Syndrome, Surgical Oncology, Japanese Patients +8
Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors
Sachi Morita, Satoshi Oizumi, Hironobu Minami et al. · Investigational New Drugs · 2011 · 42 citations
Oncology, Dose-escalating Study, Pharmacology +6
1–5 of 13